Business Wire

VIKING-MALT

1.2.2024 09:01:30 CET | Business Wire | Press release

Share
Viking Malt partners up with Improvin’ to reduce supply chain emissions in barley

Viking Malt has set Science Based Targets, committing to a 42% reduction in greenhouse gas emissions from its own activities (Scope 1 & 2) by 2030. However, the majority of Viking Malt’s total emissions, 87%, are Scope 3 emissions from their suppliers, mainly occurring on-farm.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240201888552/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Viking Malt, a globally acknowledged producer of malt, is introducing a new sustainability performance platform, developed by the Swedish technology company Improvin’. Photo: Viking Malt.

Many of Viking Malt’s customers are large enough to have reduction targets covering even their Scope 3 emissions. To support their clients in achieving this goal, Viking Malt is committed to working with its stakeholders across the supply chain, identifying areas for emissions reductions and adjusting processes and practices.

With barley sourced from farmers across Finland, Sweden, Denmark, Poland and Lithuania, Viking Malt has been seeking ways to effectively measure and reduce these emissions.

Annika Wilhelmson, VP of Sustainability, Innovation & Marketing at Viking Malt Group: “Our farmers are central to our sustainability journey. With this new platform, we're empowering over 1200 farmers across Europe to actively engage in climate-smart and sustainable farming. This enables us to track and validate the impact of their sustainable practices effectively and fosters a collaborative approach to reducing emissions.”

The new platform provides Viking Malt with a detailed overview of the farms’ sustainability performance, setting a foundation for sustainable farming initiatives in which growers can adjust their practices based on feedback that builds on real-time data.

With the platform’s scalable data collection, farmer reporting becomes easy. “We want our farmers to be able to focus on sustainable and profitable agriculture, not extensive reporting,” Annika emphasizes.

The new platform equips Viking Malt with a verified ingredient footprint, biodiversity data and supply chain insights that they can share with their network of breweries, distilleries and food manufacturers. Viking Malt expects this transparency to drive positive change across the industry.

Annika concludes: “Our commitment to sustainable food and beverage production is shared by the industry. Success requires a collaborative approach throughout, and even beyond, our own value chain. We're excited to lead and inspire our partners and customers on this journey.”

Niklas Wallsargård, CEO of Improvin’ adds: “We're both proud and excited to work with Viking Malt, a family company showing deep commitment to drive sustainable impact through their products. Together, we can drive a meaningful change in this industry.”

About Viking Malt

Viking Malt is a globally acknowledged producer of malt for breweries, distilleries, and food manufacturers. With six malt houses in Sweden, Denmark, Finland, Lithuania, and Poland, Viking Malt offers a diverse range of malt varieties, catering to the unique needs of their customers. The company advocates for increased sustainability through malt by promoting regenerative farming practices, continuously improving energy and water efficiency in the malting process, reducing emissions, and leading innovation in new types of malts.

About Improvin’

Improvin’ is a Swedish technology company providing a sustainability performance platform for the agri-food industry. Food brands, processors and mills use the platform to quantify, verify and report emissions from their primary production and collaborate with their suppliers to reduce emissions and enhance biodiversity. Improvin's digital infrastructure enables agri-food businesses to incorporate sustainability into their existing sourcing processes while meeting regulatory standards for reporting with primary data.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240201888552/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye